Cargando…

Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children

BACKGROUND: Praziquantel is the drug of choice in preventive chemotherapy targeting schistosomiasis. Increasing large-scale administration of praziquantel requires monitoring of drug efficacy to detect early signs of development of resistance. Standard protocols for drug efficacy monitoring are nece...

Descripción completa

Detalles Bibliográficos
Autores principales: Stete, Katarina, Krauth, Stefanie J, Coulibaly, Jean T, Knopp, Stefanie, Hattendorf, Jan, Müller, Ivan, Lohourignon, Laurent K, Kern, Winfried V, N’Goran, Eliézer K, Utzinger, Jürg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558406/
https://www.ncbi.nlm.nih.gov/pubmed/23259435
http://dx.doi.org/10.1186/1756-3305-5-298
_version_ 1782257428874657792
author Stete, Katarina
Krauth, Stefanie J
Coulibaly, Jean T
Knopp, Stefanie
Hattendorf, Jan
Müller, Ivan
Lohourignon, Laurent K
Kern, Winfried V
N’Goran, Eliézer K
Utzinger, Jürg
author_facet Stete, Katarina
Krauth, Stefanie J
Coulibaly, Jean T
Knopp, Stefanie
Hattendorf, Jan
Müller, Ivan
Lohourignon, Laurent K
Kern, Winfried V
N’Goran, Eliézer K
Utzinger, Jürg
author_sort Stete, Katarina
collection PubMed
description BACKGROUND: Praziquantel is the drug of choice in preventive chemotherapy targeting schistosomiasis. Increasing large-scale administration of praziquantel requires monitoring of drug efficacy to detect early signs of development of resistance. Standard protocols for drug efficacy monitoring are necessary. Here, we determined the optimal time point for praziquantel efficacy assessment against Schistosoma haematobium and studied the dynamics of infection parameters following treatment. METHODS: Ninety school-aged children from south Côte d’Ivoire with a parasitologically confirmed S. haematobium infection were treated with a single oral dose of praziquantel (40 mg/kg) and followed up for 62 days post-treatment. Urine samples were collected on 23 schooldays during this period and were subjected to visual examination (macrohaematuria), urine filtration and microscopy (S. haematobium eggs) and reagent strip testing (microhaematuria, proteinuria and leukocyturia). RESULTS: Observed cure and egg reduction rates were highly dependent on the time point post-treatment. Egg reduction rates were high (>97%) in weeks 3–9 post-treatment. Cure rates were highest in weeks 6 (92.9%) and 9 (95.0%) post-treatment. The prevalence of infection-associated parameters decreased after treatment, reaching a minimum of 2.4% in weeks 5 (proteinuria) and 7 (leukocyturia) post-treatment, and 16.3% at the end of week 8 (microhaematuria). Macrohaematuria disappeared between weeks 3 and 6 post-treatment. CONCLUSIONS: For monitoring praziquantel efficacy against S. haematobium, we recommend that the cure rate is assessed at week 6 post-treatment. The egg reduction rate can be evaluated earlier, from day 14 post-treatment onwards. Reagent strips are a useful additional tool for evaluating treatment outcomes in areas with high endemicity, preferably at weeks 5 and 6 post-treatment. The delayed decrease of microhaematuria confirms that lesions in the urinary tract persist longer than egg excretion post-treatment.
format Online
Article
Text
id pubmed-3558406
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35584062013-01-31 Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children Stete, Katarina Krauth, Stefanie J Coulibaly, Jean T Knopp, Stefanie Hattendorf, Jan Müller, Ivan Lohourignon, Laurent K Kern, Winfried V N’Goran, Eliézer K Utzinger, Jürg Parasit Vectors Research BACKGROUND: Praziquantel is the drug of choice in preventive chemotherapy targeting schistosomiasis. Increasing large-scale administration of praziquantel requires monitoring of drug efficacy to detect early signs of development of resistance. Standard protocols for drug efficacy monitoring are necessary. Here, we determined the optimal time point for praziquantel efficacy assessment against Schistosoma haematobium and studied the dynamics of infection parameters following treatment. METHODS: Ninety school-aged children from south Côte d’Ivoire with a parasitologically confirmed S. haematobium infection were treated with a single oral dose of praziquantel (40 mg/kg) and followed up for 62 days post-treatment. Urine samples were collected on 23 schooldays during this period and were subjected to visual examination (macrohaematuria), urine filtration and microscopy (S. haematobium eggs) and reagent strip testing (microhaematuria, proteinuria and leukocyturia). RESULTS: Observed cure and egg reduction rates were highly dependent on the time point post-treatment. Egg reduction rates were high (>97%) in weeks 3–9 post-treatment. Cure rates were highest in weeks 6 (92.9%) and 9 (95.0%) post-treatment. The prevalence of infection-associated parameters decreased after treatment, reaching a minimum of 2.4% in weeks 5 (proteinuria) and 7 (leukocyturia) post-treatment, and 16.3% at the end of week 8 (microhaematuria). Macrohaematuria disappeared between weeks 3 and 6 post-treatment. CONCLUSIONS: For monitoring praziquantel efficacy against S. haematobium, we recommend that the cure rate is assessed at week 6 post-treatment. The egg reduction rate can be evaluated earlier, from day 14 post-treatment onwards. Reagent strips are a useful additional tool for evaluating treatment outcomes in areas with high endemicity, preferably at weeks 5 and 6 post-treatment. The delayed decrease of microhaematuria confirms that lesions in the urinary tract persist longer than egg excretion post-treatment. BioMed Central 2012-12-21 /pmc/articles/PMC3558406/ /pubmed/23259435 http://dx.doi.org/10.1186/1756-3305-5-298 Text en Copyright ©2012 Stete et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Stete, Katarina
Krauth, Stefanie J
Coulibaly, Jean T
Knopp, Stefanie
Hattendorf, Jan
Müller, Ivan
Lohourignon, Laurent K
Kern, Winfried V
N’Goran, Eliézer K
Utzinger, Jürg
Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title_full Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title_fullStr Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title_full_unstemmed Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title_short Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
title_sort dynamics of schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558406/
https://www.ncbi.nlm.nih.gov/pubmed/23259435
http://dx.doi.org/10.1186/1756-3305-5-298
work_keys_str_mv AT stetekatarina dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT krauthstefaniej dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT coulibalyjeant dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT knoppstefanie dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT hattendorfjan dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT mullerivan dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT lohourignonlaurentk dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT kernwinfriedv dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT ngoraneliezerk dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren
AT utzingerjurg dynamicsofschistosomahaematobiumeggoutputandassociatedinfectionparametersfollowingtreatmentwithpraziquantelinschoolagedchildren